A new multitarget molecule designed with high potential in future treatments for Alzheimer's disease
Researchers at Universitat Autònoma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the ß-amyloid protein, involved in Alzheimer's disease. At the same time, ASS234 stimulates the cholinergic and monoaminergic transmission, key factors involved in the cognitive function. In addition, ASS234 is able to cross the bloodbrain barrier with an elevated multipotent profile designed on basis of donepezil (Aricept), one of the few effective drugs in palliative and symptomatic treatments of the disease.
In the development of this new molecule, researchers used the strategy of "multipotent drugs", capable of acting simultaneously on different targets in the brain involved in this neurodegenerative disease, given that the paradigm used in the design of drugs based on the strategy of "one drug, one target" has shown to be unsuitable in offering satisfactory results.
ASS234 was developed as a hybrid of two known molecules. One of them, donepezil, is currently used to treat Alzheimer's disease, and the other, PF9601N compound, is an inhibitor of the monoamino oxidase B (MAO B) enzyme, patented and developed by researchers at UAB and CSIC, with proven neuroprotective effects in different experimental models of Parkinson's disease.
The research was directed by Mercedes Unzeta, researcher of the Department of Biochemistry and Molecular Biology and of the Institute of Neurosciences (INc) at UAB, José Luis Marco Contelles, CSIC researcher at the Institute of General Organic Chemistry (IQOG), and F. Javier Luque, researcher of the Department of Physico-Chemistry at the Faculty of Pharmacy and the Institute of Biomedicine of the UB (IBUB). All three researchers have worked for years on the design, synthesis and biological evaluation of new multipotent molecules capable of stimulating neural transmissions and at the same time having neuroprotective effects. ASS234 acts on both of these processes.
The biochemical activity and pharmacological potential of the molecule was exhaustively characterised by Irene Bolea (UAB) and synthesised by Abdelouahid Samadi (CSIC). Previous studies on the interactions of ASS234 with its possible targets were carried out by Jordi Juárez-Jiménez (UB). The ASS234 molecule has been patented by all three institutions.
This molecule could be much more efficient than other compounds used to stimulate neural transmission and simultaneously act on different brain targets. To date, in vitro investigations conducted at UAB have demonstrated that ASS234, in addition to being able to inhibit monoamino oxidases A and B, also act on the enzymes acetylcholinesterase and butyrylcholinesterase, thus helping to boost levels of acetylcholine, a neurotransmitter deficient in patients with Alzheimer's. The latest results obtained indicate that ASS234 also reduces aggregation of the ß-amyloid protein which gives way to the appearance of senile plaques characteristic of the disease.
Other recent studies conducted by researchers of the CSIC Cajal Institute and the University of Lodz, Poland, have demonstrated that ASS234 is able to cross the blood-brain barrier and improves memory in mice.
All studies conducted to date make clear that ASS234 is a promising multitarget molecule due to its potential therapeutic effects on patients with Alzheimer's disease. As affirmed by Dr Unzeta and Dr Marco Contelles, ASS234 "a priori appears as a derivative of donepezil, which contains not only its virtues but possesses also a potential multipotent profile drug, which could make it a more efficient drug for the treatment of this disease".
More information: 1.- "The multitarget compound ASS234 reduces A? fibrillogenesis and protects SH-SY5Y cells from A? toxicity." Irene Bolea, Alejandro Gella, Abdelouahid Samadi, Jose Luis Marco and Mercedes Unzeta. (In preparation)
2.- "Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: Synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine." Abdelouahid Samadi, Cristóbal de los Ríos, Irene Bolea, Mourad Chioua, Isabel Iriepa, Ignacio Moraleda, Manuela Bartolini, Vincenza Andrisano, Enrique Gálvez, Carolina Valderas, Mercedes Unzeta, José Marco-Contelles. European Journal of Medicinal Chemistry 2012, 52, 251-262
3.- "Synthesis, Biological Evaluation and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids, as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer's Disease." I. Bolea, J. Juárez-Jiménez, C. de los Ríos, M. Chioua, R. Pouplana, F. J. Luque, M. Unzeta, J. Marco-Contelles, and A. Samadi Journal of Medicinal Chemistry 2011, 54, 8251-8270
4.- "Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease." Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, Bastida A, Esteban E, Unzeta M, Gálvez E and Marco-Contelles J. Eur J Med Chem 46(9):4665-4668
Provided by Universitat Autonoma de Barcelona
- New discoveries in cell aging Jan 23, 2012 | not rated yet | 0
- Researchers have identified a gene with a key role in neuronal survival Apr 16, 2012 | not rated yet | 0
- Alzheimer's drug begins human trials Jun 27, 2007 | not rated yet | 0
- New test to study proteins involved in neurodegenerative diseases Feb 01, 2011 | not rated yet | 0
- Protein in the brain could be a key target in controlling Alzheimer's Jan 25, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Question of reflection and transmission of TEM wave in normal incidenc
1 hour ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
2 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
Normal force for a lever model
3 hours ago My model is a lever on a table top. One arm is horizontal on the table, while the other arm is raised at an angle alpha. I'm assuming the weight of...
gravity is std. therefore can we rate a 'mass at height' by watts?
8 hours ago For example.... wind turbines are primarily listed by their wattage (1.5MW etc.) Presumably their output is varied according to rotational speed, so...
Calculating on-axis elements of a solenoid
20 hours ago I wanted to mention that this solenoid has many winds over many layers. The thickness of the windings is 2.4 inches coming off of the engineering...
latitude & longitude & air pressure
22 hours ago Hi there, I have a peculiar question. Imagine that you are in a earth position, obtained by google, that gives you the latitude and longitude....
- More from Physics Forums - Classical Physics
More news stories
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Alzheimer's disease & dementia 2 hours ago | 5 / 5 (3) | 0 |
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
Alzheimer's disease & dementia 4 hours ago | not rated yet | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
Alzheimer's disease & dementia 4 hours ago | 5 / 5 (1) | 0 |
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
Alzheimer's disease & dementia 7 hours ago | not rated yet | 0
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Alzheimer's disease & dementia May 21, 2013 | 5 / 5 (7) | 0 |
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
47 minutes ago | not rated yet | 0 |
Two out of five medical students have an unconscious bias against obese people, according to a new study by researchers at Wake Forest Baptist Medical Center. The study is published online ahead of print in the Journal of ...
21 minutes ago | not rated yet | 0
International efforts to combat a new pneumonia-like virus that has now killed 22 people are being slowed by unclear rules and competition for the potentially profitable rights to disease samples, the head ...
22 minutes ago | not rated yet | 0
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
58 minutes ago | 5 / 5 (1) | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
1 hour ago | not rated yet | 0
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
1 hour ago | not rated yet | 0